Glenmark Pharmaceuticals has been granted final approval by the United States Food & Drug Administration (USFDA) for Clobetasol Propionate Foam, 0.05% (Emulsion Formulation), a generic version of Olux1‐E Foam, 0.05%, of Mylan Pharmaceuticals Inc.
According to IQVIATM sales data for the 12 month period ending July 2019, the Olux‐E Foam, 0.05% market2 achieved annual sales of approximately $11.1 million.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
